Astrana Health, Inc. ASTH
36.37
1.93
5.60%
as of 25 Sep
- Market cap
- $1.7B
- P/E
- 43.6×
Follow ASTH
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
1.27% | 2.98% | 3.86% | 5.03% | |
| 0.54% | 1.26% | 1.64% | 2.18% | ||
ROIC |
2.77% | 3.50% | 3.96% | 4.56% | |
Return on Tangible Assets |
3.08% | 7.36% | 9.50% | 17.32% | |
Average Days of Receivables |
49.29 | 46.19 | 51.28 | 46.45 | |
Free Cash Flow per Share |
1.97 | 2.13 | 3.17 | 1.92 | |
Free Cash Flow |
96.96 | 104.49 | 154.99 | 94.38 | |
Capital Expenditures |
(9.57) | (10.11) | (11.04) | (13.49) | |
Piotroski F-Score |
4.00 | 4.00 | 4.00 | 5.00 | |
| Other line items | |||||
Cash ROIC |
4.63% | 5.07% | 7.15% | 4.95% | |
Accounts Receivable Turnover |
9.39 | 8.75 | 8.56 | 9.00 | |
Accounts Payable Turnover |
17.07 | 18.81 | 19.27 | 18.83 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
29.45 | 25.18 | 25.65 | 26.07 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
(0.68) | (0.39) | (0.38) | (0.35) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
6.86% | 6.83% | 6.67% | 6.20% | |
Share Based Compensation of Revenue |
1.47% | 1.21% | 1.15% | 1.06% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
11.17 | 5.10 | 5.49 | 2.66 | |
Depreciation/Fixed assets |
0.73 | 0.87 | 0.99 | 1.08 | |
Capex/Depreciation |
(0.23) | (0.20) | (0.19) | (0.20) | |
Revenue per Share |
58.85 | 64.83 | 72.18 | 78.27 | |
Operating CF per Share |
2.16 | 2.34 | 3.40 | 2.20 | |
Capex per Share |
(0.19) | (0.21) | (0.23) | (0.27) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.33% | 0.71% | 0.86% | 1.05% |
Columns are period end dates